NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
A research team is shedding new light on Bacillus Calmette-Guerin (BCG), a decades-old bladder cancer treatment, which is also given as vaccine against tuberculosis. The findings could help improve ...
Bladder cancer is the ninth most prevalent cancer worldwide 1, and approximately 75% of cases are non-muscle invasive bladder cancer (NMIBC) 2,3. High-risk NMIBC is treated with transurethral ...
In patients with non-muscle-invasive bladder cancer, especially those with carcinoma in situ (CIS), most recurrences, progression events, and cystectomies occurred in those with bacillus ...
How can a tuberculosis vaccine also treat cancer—and potentially make other immunotherapies more effective? That’s the question researchers at Memorial Sloan Kettering Cancer Center (MSK) and Weill ...
BCG might be superior to sequential intravesical gemcitabine-docetaxel for reducing the risk of recurrence in patients with high-grade intermediate-risk NMIBC. Given the recent global shortage of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results